Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia - Test2 - elhamkhani - TriplyDB

Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia

Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia

http://www.wikidata.org/entity/Q28379542

about

PML nuclear bodies Common properties of nuclear body protein SP100 and TIF1alpha chromatin factor: role of SUMO modification Sp100 interacts with ETS-1 and stimulates its transcriptional activity Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence.Arsenic-induced SUMO-dependent recruitment of RNF4 into PML nuclear bodies Leukemia-associated retinoic acid receptor alpha fusion partners, PML and PLZF, heterodimerize and colocalize to nuclear bodies ZIP kinase triggers apoptosis from nuclear PML oncogenic domains RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation TRIM family proteins: retroviral restriction and antiviral defence Viral immediate-early proteins abrogate the modification by SUMO-1 of PML and Sp100 proteins, correlating with nuclear body disruption Conjugation with the ubiquitin-related modifier SUMO-1 regulates the partitioning of PML within the nucleus.Arsenic trioxide is a potent inhibitor of the interaction of SMRT corepressor with Its transcription factor partners, including the PML-retinoic acid receptor alpha oncoprotein found in human acute promyelocytic leukemia Caspase cleavage of MST1 promotes nuclear translocation and chromatin condensation The human and African green monkey TRIM5alpha genes encode Ref1 and Lv1 retroviral restriction factor activities From an old remedy to a magic bullet: molecular mechanisms underlying the therapeutic effects of arsenic in fighting leukemia The cell biology of disease: Acute promyelocytic leukemia, arsenic, and PML bodies Arsenic Trioxide Inhibits Hepatitis C Virus RNA Replication through Modulation of the Glutathione Redox System and Oxidative Stress Targeting of leukemia-initiating cells in acute promyelocytic leukemia PML protein isoforms and the RBCC/TRIM motif PML interaction with p53 and its role in apoptosis and replicative senescence PIC-1/SUMO-1-modified PML-retinoic acid receptor alpha mediates arsenic trioxide-induced apoptosis in acute promyelocytic leukemia Role of promyelocytic leukemia (PML) sumolation in nuclear body formation, 11S proteasome recruitment, and As2O3-induced PML or PML/retinoic acid receptor alpha degradation Arsenic trioxide induces apoptosis of HPV16 DNA-immortalized human cervical epithelial cells and selectively inhibits viral gene expression Arsenic trioxide induces apoptosis in neuroblastoma cell lines through the activation of caspase 3 in vitro Arsenic-induced apoptosis in malignant cells in vitro Apoptosis and growth inhibition in malignant lymphocytes after treatment with arsenic trioxide at clinically achievable concentrations TRIM5 alpha cytoplasmic bodies are highly dynamic structures.The tumor suppressor cybL, a component of the respiratory chain, mediates apoptosis induction Pathologic, cytogenetic and molecular assessment of acute promyelocytic leukemia patients treated with arsenic trioxide (As2O3).Retinoic acid, but not arsenic trioxide, degrades the PLZF/RARalpha fusion protein, without inducing terminal differentiation or apoptosis, in a RA-therapy resistant t(11;17)(q23;q21) APL patient.Retinoic acid and arsenic synergize to eradicate leukemic cells in a mouse model of acute promyelocytic leukemia Arsenic trioxide triggers a regulated form of caspase-independent necrotic cell death via the mitochondrial death pathway.Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.Maintenance therapy with all-trans retinoic acid and arsenic trioxide improves relapse-free survival in adults with low- to intermediate-risk acute promyelocytic leukemia who have achieved complete remission after consolidation therapy.The pathogenesis of acute promyelocytic leukaemia: evaluation of the role of molecular diagnosis and monitoring in the management of the disease.The disruption of ND10 during herpes simplex virus infection correlates with the Vmw110- and proteasome-dependent loss of several PML isoforms Modulation of p53, c-fos, RARE, cyclin A, and cyclin D1 expression in human leukemia (HL-60) cells exposed to arsenic trioxide Interactions of herpes simplex virus type 1 with ND10 and recruitment of PML to replication compartments.PTEN is a negative regulator of mitotic checkpoint complex during the cell cycle Arsenic trioxide therapy for relapsed acute promyelocytic leukemia: an useful salvage therapy.

P2860

Q22065791-89A498AE-D16B-4288-8C75-59B3CA3E345B Q24291154-434C19D2-E971-4045-9062-92B12630C6B8 Q24292513-B219C53D-76CB-4E33-A72C-481BEAB06A88 Q24297146-CD9A4BF7-A556-4E49-83A3-36BA905351FB Q24302645-12A61F06-5240-4CCF-9CE9-99E4727F793D Q24311314-BDA66BE6-4786-444A-8518-AC9C6E20A0C0 Q24315479-87C52809-3613-4F57-85E1-5A11DAE78E3C Q24320385-5CEC53C5-F0C7-4B21-8D79-3AE265AC3BA2 Q24329175-F440C379-7CA1-4BE9-894D-245A58816871 Q24527246-5F17DC7C-2A75-49A0-AEEB-73D03995CD41 Q24532901-AE44C86F-884E-4BC8-9580-9EDAF4B53B7F Q24548302-9990698D-4B94-4360-8C39-CE0782E4323A Q24555220-D2130020-C165-4DBC-A433-0E906F14EB30 Q24561930-602D18EC-81D1-4FD5-AE10-4AE6E7EF02A9 Q24605527-DC8046DE-7F40-4E15-A3DA-5BA6DFED887A Q26853348-FA55118C-4358-49B4-9E14-2E8556F90810 Q27487944-63E9F440-2DCA-492C-892C-5286F59B42C2 Q28083807-2D130D8C-4761-4C4F-9316-C92A1F920FD6 Q28204823-1FB2E257-CDAC-4F96-B70C-B1221C82741A Q28204830-4EE319C8-9470-4A77-9D37-4C0D5A9A9819 Q28343393-CCC16CD8-2A0F-4435-84AE-20CAC62D0985 Q28367104-4DF7D31F-1B20-4F54-92DB-74D088631368 Q28368210-FBDD2E61-1571-4CC3-B0FD-71C1C6361815 Q28369849-86BEB944-6B7F-488C-80F7-E928DACEEBCB Q28373408-7AD85309-026B-4D7A-9491-C332D4CE94AF Q28375997-6932AF03-C11C-465A-A6CE-6D36536F6B9D Q30479495-06D24349-0CB3-4188-A075-581CE462C973 Q30977301-6891EA85-215D-4C7A-AABD-6BA2B36124FE Q31440674-FB09E1F7-6EF2-46C8-94FB-2E13A99E6DAA Q33177365-692EA484-71DC-4B9F-8AA4-592417EDF0D4 Q33178068-C4B00211-9800-4310-8184-304501E55EF3 Q33211246-78F30986-D494-41FD-ACB1-D9EC7973D3C0 Q33551142-01C8A8EC-3F0D-40CC-AE82-DCF4C23D7CD7 Q33631350-6CEE5B57-D994-4E4D-B478-20150B7E50D8 Q33723609-ED6CD540-1841-499F-9F89-7BD0D8324499 Q33783492-B4ECDC10-CE29-4F07-97CA-17E1FCA3597E Q33791820-BFEED845-6394-475E-AEEF-ACDEE827EEFD Q33850767-CBFF62CE-71EE-47AC-B526-C9C9522151A3 Q33857310-D0078879-102B-4AF0-84E6-FCC6DD3936CF Q33929824-1E43D8AF-023A-438D-B3C2-4165B8E21B11

P2860

Arsenic-induced PML targeting onto nuclear bodies: implications for the treatment of acute promyelocytic leukemia

http://www.wikidata.org/entity/Q28379542

description

1997 nî lūn-bûn

@nan

1997 թուականի Ապրիլին հրատարակուած գիտական յօդուած

@hyw

1997 թվականի ապրիլին հրատարակված գիտական հոդված

@hy

1997年の論文

@ja

1997年論文

@yue

1997年論文

@zh-hant

1997年論文

@zh-hk

1997年論文

@zh-mo

1997年論文

@zh-tw

1997年论文

@wuu

name

Arsenic-induced PML targeting ...... f acute promyelocytic leukemia

@ast

Arsenic-induced PML targeting ...... f acute promyelocytic leukemia

@en

Arsenic-induced PML targeting ...... f acute promyelocytic leukemia

@nl

type

label

Arsenic-induced PML targeting ...... f acute promyelocytic leukemia

@ast

Arsenic-induced PML targeting ...... f acute promyelocytic leukemia

@en

Arsenic-induced PML targeting ...... f acute promyelocytic leukemia

@nl

prefLabel

Arsenic-induced PML targeting ...... f acute promyelocytic leukemia

@ast

Arsenic-induced PML targeting ...... f acute promyelocytic leukemia

@en

Arsenic-induced PML targeting ...... f acute promyelocytic leukemia

@nl

P1433

Q28379542-2CDCA657-7442-4237-B6FA-9B1CB4B9B1B5

P1476

Q28379542-097B0ECA-1115-4B7A-BC6E-577B32878B62

P2093

Q28379542-2A28EC2F-766F-4444-9824-6290B649A76F

Q28379542-54B19FD4-4433-4C4B-8C04-90375E4006AD

Q28379542-5C4EB69A-7066-4C99-AC8A-0627F71E17D9

Q28379542-A1C400F8-59B5-4CC5-934F-2229B1E9259B

Q28379542-D498D880-A2A1-46FD-BCCB-D9B4A4BC5C8F

Q28379542-F8E5DF03-9D8F-4F80-B651-E50B04FEBA8A

Q28379542-FADB0A8F-B3B6-4A42-BE7F-E32438255C7E

P2860

Q28379542-069D773B-7346-4CBD-A7DE-34AC94BB6084

Q28379542-0D84BF04-0111-48A4-97FD-9B67773FD008

Q28379542-1A385BC3-28DA-4782-BE27-BACFFF505961

Q28379542-1B5907CB-A901-4088-80DF-371F0C45B9DF

Q28379542-27BFDDFA-D5BD-463C-A369-083DA40FF921

Q28379542-2875B651-D881-42E3-A161-748257E6170F

Q28379542-2A44A7BA-0DDF-41EB-9C6B-396F09458C34

Q28379542-2DBB4856-4ABB-48F4-A13F-0530A445334D

Q28379542-34EFA90D-7A18-43C3-9ECC-24BC9C07B945

Q28379542-37473201-32DB-4D99-838E-44E5E9D1711E

P304

Q28379542-D614168E-DEC9-4868-B73A-2E961540D6EB

P31

Q28379542-1DB8E0D4-F083-4BD9-8BBC-55EF2DF1EA1F

P356

Q28379542-20350609-FCF4-4D19-A5BD-4D2CE7CB8061

P407

Q28379542-D206122B-BC2A-4340-8BAC-AAFF5D5F6CDE

P433

Q28379542-B8AF8595-D2AF-4FCE-A83A-5522F52EC05F

P478

Q28379542-CA10CE61-5F72-4534-9F1C-7A052476CBFB

P50

Q28379542-AC1A2C87-5DAF-464B-AC7C-D2D135DBA6C1

P577

Q28379542-1701DF98-773F-45FF-A596-61EB7525615A

P5875

Q28379542-C8D4891A-6AA9-43D7-8CDF-BDEB3BD0A2B4

P698

Q28379542-130F8F8E-150B-47E8-9C67-E973A88F82FC

P921

Q28379542-8865BE03-14ED-451E-834A-5A2F583C6D41

P932

Q28379542-0A863685-186A-448C-BF35-8152F639AFA0

P356

P1433

Proceedings of the National Academy of Sciences of the United States of America

P1476

Arsenic-induced PML targeting ...... f acute promyelocytic leukemia

@en

P2093

F Quignon

http://www.w3.org/2001/XMLSchema#string

H de Thé

http://www.w3.org/2001/XMLSchema#string

J Zhu

http://www.w3.org/2001/XMLSchema#string

M H Koken

http://www.w3.org/2001/XMLSchema#string

M K Chelbi-Alix

http://www.w3.org/2001/XMLSchema#string

Z Chen

http://www.w3.org/2001/XMLSchema#string

Z Y Wang

http://www.w3.org/2001/XMLSchema#string

P2860

Molecular characterization of NDP52, a novel protein of the nuclear domain 10, which is redistributed upon virus infection and interferon treatment

Isolation and characterization of cDNA encoding a human nuclear antigen predominantly recognized by autoantibodies from patients with primary biliary cirrhosis

PML, a growth suppressor disrupted in acute promyelocytic leukemia

Structure, localization and transcriptional properties of two classes of retinoic acid receptor alpha fusion proteins in acute promyelocytic leukemia (APL): structural similarities with a new family of oncoproteins

Nuclear dot antigens may specify transcriptional domains in the nucleus

Identification of a novel nuclear domain

Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.

PIC 1, a novel ubiquitin-like protein which interacts with the PML component of a multiprotein complex that is disrupted in acute promyelocytic leukaemia

The PML-RAR alpha fusion mRNA generated by the t(15;17) translocation in acute promyelocytic leukemia encodes a functionally altered RAR

Retinoic acid regulates aberrant nuclear localization of PML-RAR alpha in acute promyelocytic leukemia cells

P304

3978-83

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1073/PNAS.94.8.3978

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

94

http://www.w3.org/2001/XMLSchema#string

P50

P577

1997-04-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

14109889

http://www.w3.org/2001/XMLSchema#string

P698

9108090

http://www.w3.org/2001/XMLSchema#string

P921

P932

20553

http://www.w3.org/2001/XMLSchema#string